Confidential and non-confidential drug rebates in Switzerland, 2013–2023: empirical analysis of drug rebates, trends over time and re-evaluations Authors: Noah Rohner, Cascal Herrle, Luca Locher, Kerstin N. Vokinger Published: 2024 Countries introduced confidential drug rebates with the objective to achieve lower drug prices in their country. However, studies and the WHO outline the importance of transparent prices.1,2 Confidential rebates may result in an overpayment because manufacturers may anticipate the presence of a rebate and enter the negotiation with a higher price or because there is a lack of an administrative and technical system to recoup such rebates.3 Confidential rebates may also result in an overpayment in countries that rely on external reference pricing. Reference pricing is usually based on list prices, which may be substantially higher than the actual prices.4 The objective was to analyze which drugs were granted confidential and non-confidential rebates in Switzerland 2013–2023, if the rebate status changed over time, and if drugs with rebates were re-evaluated within the determined timeframe. We identified all drugs with an introduced confidential or non-confidential rebate 2013–2023 using the public database of the Federal Office for Public Health.5 We collected information on the date of first reimbursement and first granted rebate, confidentiality or non-confidentiality, dates for changes in the rebate status, therapeutic area, and whether a re-evaluation date for the rebate was defined and if so, the dates of the defined time duration and re-evaluation dates. Trends were analyzed using descriptive statistics. 87 drugs were included in our cohort. 45/87 (52%) drugs were granted a confidential, 42/87 (48%) a non-confidential rebate, most of them (55/87, 63%) targeted cancer disorders (Supplementary Fig. S1 and Table S1). The number of drugs with rebates increased over the past years, and since 2020 more drugs with confidential than non-confidential rebates have been introduced in Switzerland (Supplementary Fig. S1). 85/87 (98%) drugs maintained a rebate until end of the study period. 77/87 (89%) drugs had at least once a determined rebate timeframe, 44/77 (57%) were drugs with confidential rebates and 33/77 (43%) with non-confidential rebates (Fig. 1). Median duration of the determined rebate timeframe was 632 days (mean: 603 days) for drugs with confidential rebates, and 658 days (mean: 565 days) for drugs with non-confidential rebates. For approximately one quarter of the drugs (12/44) with a confidential rebate and a defined time duration and more than two thirds of the drugs (25/33) with a non-confidential rebate, the deadline expired, and re-evaluation occurred either after the deadline or has not (yet) been conducted (Fig. 1).Fig. 1Re-evaluation of rebates within and outside deadline. Notes: Drugs with rebates and information whether the rebate had a defined time duration until re-evaluation and whether this deadline was met or exceeded. Drugs with an asterisk had a confidential rebate (at the time of first granted rebate). Re-evaluation was defined as changes in the “Limitatio” in the special list (www.spezialitaetenliste.ch). Re-evaluation of rebates within and outside deadline. Notes: Drugs with rebates and information whether the rebate had a defined time duration until re-evaluation and whether this deadline was met or exceeded. Drugs with an asterisk had a confidential rebate (at the time of first granted rebate). Re-evaluation was defined as changes in the “Limitatio” in the special list (www.spezialitaetenliste.ch). If a drug was granted a rebate for more than one indication, we only included the first indication that was granted a rebate in our study cohort, i.e., on indication level we underestimate the number of granted rebates. The study findings demonstrate that the number of drugs with confidential rebates has increased despite concerns raised in previous studies and by the WHO. Furthermore, the deadline for re-evaluation of the granted rebate often expired. Ideally, Switzerland will change its policy towards more drug pricing transprency. At the least, re-evaluations should be conducted regularly and timely, and as long as transparency is not achieved, external reference pricing fails its objective and should not be used for these drugs as a pricing determinant. Contributors Conceptualization, funding acquisition, methodology, project administration, and first draft were performed by KNV. Conceptualization, data curation and draft revision was performed by NR. Data curation was performed by CH. Data analysis was performed by LL. KNV supervised the project. CH and LL accessed and verified the underlying data reported in the manuscript. All authors had full access to all the data in the study, read and approved the final manuscript. Data sharing statement Data used for the analyses is available author upon reasonable request (luca.locher@ius.uzh.ch). Declaration of interests The authors declare no competing interests.